Context
Personalized oncology is transforming the therapeutic landscape of patients suffering from stage IV cancer. Large scale analyses like genomics and transcriptomics based on next generation sequencing, proteomics, multiplexed immuno-histo-chemistry and other -omics have to be tightly integrated to guide rational treatment decisions.
Patients under immune therapies are monitored regularly to ensure lack of side effects and tolerance to therapy. Therefore, immune-related adverse events (irAEs) are recorded during the whole study. Little is known about irAEs occurrence, and few risk factors have been described. Here, we want to test if the medication background of the patients has an effect on the occurrence of irAEs. We will use the data provided by a BMS trial, that has a strict follow up on patients.
Purpose of the study
Identify some baseline medications as independent risk factors for the occurrence of specific irAEs, and identify the physiopathology behind it.
Methods
Selection of the patients’ baseline medications will allow to test the effect on the occurrence of irAEs. IrAEs are selected in order to keep only the grade 2 and greater AEs that are quoted as immune-related.
Secondly, we want to test if the results we obtain are reproducible: we will try to validate the results we obtain with using data provided by the CHUV.
Statistical analysis
The statistical analysis will be performed using R software. Fisher exact tests will be applied in order to test whether or not the baseline medications affect the occurrence of irAEs. Secondly, Welch test will be performed to see if some selected biological biomarkers differ in function of baseline medications that appear to affect the occurrence of irAEs.